The European consortium Psych-STRATA is funded by the European Union (HORIZON-HLTH-2021-STAYHLTH-01) and focusses on the molecular foundations of treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depressive disorder as well as on early detection and early treatment of these difficult to treat disorders. Psych-STRATA has members of 26 insitutions across Germany, Europe, Israel and Australia and is coordinated at the University of Münster (B.Baune).

Comorbidity and overlap of bipolar disorder/depression and ADHD – translating affective neuroscience approaches in real-life experiments and clinical trials.

PRIME is a European consortium which aims to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders, such as affective disorders. It will generate innovative diagnostic and treatment strategies to improve the monitoring and clinical outcomes of patients.

This international multicenter project studies the effect of lifestyle (diet and physical activity) on mental health in general, and on affective disorders in particular.

European Multicenter Study on precision medicine regarding lithium treatment in bipolar disorder.

The strategic goal is to provide an enhanced understanding on irritable bowel syndrome and comorbidities with depression and anxiety. This is done by thorough clinical and psychosocial characterization of patients. Mechanisms of intestinal and central nervous system interaction on the genetic, endocrine and immune level are studied.

The aim of PSYSCAN is to improve the care of patients with psychiatric disorders. This goal will be achieved by developing a neuroimaging-based tool which will help physicians in a clinical setting.

IMAGEN combines brain imaging, genetics, and psychiatry to increase our understanding of adolescent brain development and behaviour – namely, sensitivity to rewards, impulsivity, and emotional processing.